181 related articles for article (PubMed ID: 34981056)
21. Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant.
Zhou Z; Du P; Li N; Xiong X; Tang S; Dai Q; Wang T; Yu M; Man M; Lam K; Baptista-Hon DT; Tai WH; Monteiro O; Ng WS; Lee UM; Liu Z; Zhang K; Li G
MedComm (2020); 2022 Jun; 3(2):e143. PubMed ID: 35592756
[TBL] [Abstract][Full Text] [Related]
22. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
Garcia-Beltran WF; St Denis KJ; Hoelzemer A; Lam EC; Nitido AD; Sheehan ML; Berrios C; Ofoman O; Chang CC; Hauser BM; Feldman J; Gregory DJ; Poznansky MC; Schmidt AG; Iafrate AJ; Naranbhai V; Balazs AB
medRxiv; 2021 Dec; ():. PubMed ID: 34931201
[TBL] [Abstract][Full Text] [Related]
23. mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines.
Zhang B; Huo J; Huang Y; Teo SY; Duan K; Li Y; Toh LK; Lam KP; Xu S
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891221
[TBL] [Abstract][Full Text] [Related]
24. Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals.
Maeda K; Amano M; Uemura Y; Tsuchiya K; Matsushima T; Noda K; Shimizu Y; Fujiwara A; Takamatsu Y; Ichikawa Y; Nishimura H; Kinoshita M; Matsumoto S; Gatanaga H; Yoshimura K; Oka SI; Mikami A; Sugiura W; Sato T; Yoshida T; Shimada S; Mitsuya H
medRxiv; 2021 Jul; ():. PubMed ID: 34373860
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.
Alidjinou EK; Demaret J; Corroyer-Simovic B; Labreuche J; Goffard A; Trauet J; Lupau D; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
Lancet Reg Health Eur; 2022 Jun; 17():100385. PubMed ID: 35469147
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster.
Chantasrisawad N; Puthanakit T; Kornsitthikul K; Jaru-Ampornpan P; Tawan M; Matapituk P; Sophonphan J; Anugulruengkitt S; Tangsathapornpong A; Katanyutanon A;
Vaccine X; 2022 Dec; 12():100221. PubMed ID: 36213592
[TBL] [Abstract][Full Text] [Related]
27. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
[TBL] [Abstract][Full Text] [Related]
28. Levels and durability of neutralizing antibodies against SARS-CoV-2 Omicron and other variants after ChAdOx-1 or BNT162b2 booster in CoronaVac-primed elderly individuals.
Takheaw N; Liwsrisakun C; Laopajon W; Pata S; Chaiwong W; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
Heliyon; 2023 Apr; 9(4):e15653. PubMed ID: 37095993
[TBL] [Abstract][Full Text] [Related]
29. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant.
Edara VV; Lai L; Sahoo MK; Floyd K; Sibai M; Solis D; Flowers MW; Hussaini L; Ciric CR; Bechnack S; Stephens K; Mokhtari EB; Mudvari P; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Graham BS; Wrammert J; Douek DC; Boritz E; Pinsky BA; Suthar MS
bioRxiv; 2021 May; ():. PubMed ID: 34013272
[TBL] [Abstract][Full Text] [Related]
30. Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant.
Oh SJ; O SW; Choi YJ; Kim JM; Kim D; Kim IH; Park AK; Kim HM; Rhee JE; Jang YR; Yoo CK; Kim JY; Kim EJ
J Clin Virol; 2022 Oct; 155():105253. PubMed ID: 35988369
[TBL] [Abstract][Full Text] [Related]
31. Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine.
Debes AK; Xiao S; Egbert ER; Caturegli P; Sitaras I; Pekosz A; Milstone AM
medRxiv; 2022 Jan; ():. PubMed ID: 35132427
[TBL] [Abstract][Full Text] [Related]
32. Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination.
Bonura F; Genovese D; Amodio E; Calamusa G; Sanfilippo GL; Cacioppo F; Giammanco GM; De Grazia S; Ferraro D
Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746482
[TBL] [Abstract][Full Text] [Related]
33. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
Syed AM; Ciling A; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Taha TY; Tabata T; Chen IP; Ott M; Doudna JA
medRxiv; 2022 Jan; ():. PubMed ID: 34981067
[TBL] [Abstract][Full Text] [Related]
34. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
Planas D; Saunders N; Maes P; Guivel-Benhassine F; Planchais C; Buchrieser J; Bolland WH; Porrot F; Staropoli I; Lemoine F; Péré H; Veyer D; Puech J; Rodary J; Baele G; Dellicour S; Raymenants J; Gorissen S; Geenen C; Vanmechelen B; Wawina-Bokalanga T; Martí-Carreras J; Cuypers L; Sève A; Hocqueloux L; Prazuck T; Rey FA; Simon-Loriere E; Bruel T; Mouquet H; André E; Schwartz O
Nature; 2022 Feb; 602(7898):671-675. PubMed ID: 35016199
[TBL] [Abstract][Full Text] [Related]
35. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
36. Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia.
Álvarez-Díaz DA; Muñoz AL; Tavera-Rodríguez P; Herrera-Sepúlveda MT; Ruiz-Moreno HA; Laiton-Donato K; Franco-Muñoz C; Pelaez-Carvajal D; Cuellar D; Muñoz-Suarez AM; Galindo M; Arias-Ramírez EJ; Mercado-Reyes M
Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214639
[TBL] [Abstract][Full Text] [Related]
37. Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees.
Anichini G; Terrosi C; Gandolfo C; Gori Savellini G; Fabrizi S; Miceli GB; Franchi F; Cusi MG
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632563
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 mRNA Vaccine Elicits Sustained T Cell Responses Against the Omicron Variant in Adolescents.
Choi S; Kim SH; Han MS; Yoon Y; Kim YK; Cho HK; Yun KW; Song SH; Ahn B; Kim YK; Choi SH; Choe YJ; Lim H; Choi EB; Kim K; Hyeon S; Lim HJ; Kim BC; Lee YK; Choi EH; Shin EC; Lee H
Immune Netw; 2023 Aug; 23(4):e33. PubMed ID: 37670807
[TBL] [Abstract][Full Text] [Related]
39. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
Cameroni E; Saliba C; Bowen JE; Rosen LE; Culap K; Pinto D; VanBlargan LA; De Marco A; Zepeda SK; Iulio JD; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà P; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Veesler D; Snell G; Corti D
bioRxiv; 2021 Dec; ():. PubMed ID: 34931194
[TBL] [Abstract][Full Text] [Related]
40. Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination.
Hein S; Mhedhbi I; Zahn T; Sabino C; Benz NI; Husria Y; Renelt PM; Braun F; Oberle D; Maier TJ; Hildt C; Hildt E
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
